4.98
1.19%
-0.06
Dopo l'orario di chiusura:
5.00
0.02
+0.40%
Tscan Therapeutics Inc Borsa (TCRX) Ultime notizie
TScan Therapeutics's SWOT analysis: biotech stock faces pivotal year - Investing.com India
TScan Therapeutics, Inc. (NASDAQ:TCRX) Sees Significant Growth in Short Interest - MarketBeat
92,832 Shares in TScan Therapeutics, Inc. (NASDAQ:TCRX) Bought by Troluce Capital Advisors LLC - Defense World
TScan Therapeutics, Inc. (NASDAQ:TCRX) Director Barbara Klencke Acquires 5,000 Shares - Defense World
TScan therapeutics director buys $26,450 in company stock By Investing.com - Investing.com South Africa
TScan therapeutics director buys $26,450 in company stock By Investing.com - Investing.com Canada
TScan therapeutics director buys $26,450 in company stock - Investing.com
TScan therapeutics director buys $26,450 in company stock - Investing.com India
TScan therapeutics director buys $26,450 in company stock By Investing.com - Investing.com UK
940,831 Shares in TScan Therapeutics, Inc. (NASDAQ:TCRX) Purchased by Great Point Partners LLC - Defense World
Great Point Partners LLC Makes New Investment in TScan Therapeutics, Inc. (NASDAQ:TCRX) - MarketBeat
Bank of New York Mellon Corp Purchases New Shares in TScan Therapeutics, Inc. (NASDAQ:TCRX) - MarketBeat
TScan Therapeutics, Inc. (NASDAQ:TCRX) Shares Sold by Marathon Trading Investment Management LLC - Defense World
When the Price of (TCRX) Talks, People Listen - Stock Traders Daily
TCRX Stock Sees Surge of Approximately 1.08% in Last Five Days - Knox Daily
Can Tscan Therapeutics Inc Bounce Back? 52-Week Performance and Analyst Predictions - The InvestChronicle
Its Stock Has Paid Off Big Time For Tscan Therapeutics Inc - SETE News
TScan Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewswire
TScan Therapeutics to Participate in Upcoming Investor Conferences - StockTitan
TScan Therapeutics Director Acquires 18% More Stock - Simply Wall St
How To Trade (TCRX) - Stock Traders Daily
TScan Therapeutics, Inc. (NASDAQ:TCRX) Insider Zoran Zdraveski Sells 164,686 Shares of Stock - Defense World
TScan Therapeutics, Inc. (NASDAQ:TCRX) Director Acquires $27,650.00 in Stock - MarketBeat
TScan Therapeutics director buys $56,100 in company shares - Investing.com India
TScan Therapeutics director buys $56,100 in company shares - Investing.com
TScan therapeutics executive sells over $950k in company stock By Investing.com - Investing.com Canada
TScan Therapeutics: Speculative Buy With Near-Term Catalysts In Oncology (TCRX) - Seeking Alpha
TScan Therapeutics, Inc. (NASDAQ:TCRX) to Post FY2024 Earnings of ($1.07) Per Share, Lifesci Capital Forecasts - MarketBeat
FY2024 Earnings Estimate for TScan Therapeutics, Inc. Issued By Lifesci Capital (NASDAQ:TCRX) - Defense World
FY2024 EPS Estimates for TScan Therapeutics, Inc. Decreased by Analyst (NASDAQ:TCRX) - Defense World
TScan Therapeutics, Inc. Forecasted to Earn Q3 2024 Earnings of ($0.31) Per Share (NASDAQ:TCRX) - Defense World
TScan Therapeutics (NASDAQ:TCRX) Issues Quarterly Earnings Results - MarketBeat
TScan Therapeutics (NASDAQ:TCRX) Receives Buy Rating from HC Wainwright - Defense World
TScan Therapeutics (NASDAQ:TCRX) Rating Reiterated by Needham & Company LLC - Defense World
TScan Therapeutics (NASDAQ:TCRX) Receives “Outperform” Rating from Wedbush - Defense World
Expert Outlook: TScan Therapeutics Through The Eyes Of 5 Analysts - Benzinga
HC Wainwright Reiterates Buy Rating for TScan Therapeutics (NASDAQ:TCRX) - MarketBeat
TScan Therapeutics, Inc. (NASDAQ:TCRX) Shares Bought by Vanguard Group Inc. - Defense World
TScan Therapeutics (NASDAQ:TCRX) Stock Rating Reaffirmed by Needham & Company LLC - MarketBeat
TCRX Stock Earnings: TScan Therapeutics Meets EPS, Misses Revenue for Q2 2024 - InvestorPlace
TScan Therapeutics, Inc. (TCRX) Reports Q2 Loss, Lags Revenue Estimates - MSN
TScan Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update - citybiz
TScan Therapeutics, Inc. (TCRX) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance
TScan Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewswire
TScan Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update - Quantisnow
Sangamo Therapeutics (NASDAQ:SGMO) and TScan Therapeutics (NASDAQ:TCRX) Critical Survey - Defense World
(TCRX) On The My Stocks Page - Stock Traders Daily
TScan Therapeutics, Inc. (NASDAQ:TCRX) Short Interest Up 67.7% in July - MarketBeat
Trading (TCRX) With Integrated Risk Controls - Stock Traders Daily
Tocqueville Asset Management L.P. Takes $1.69 Million Position in TScan Therapeutics, Inc. (NASDAQ:TCRX) - Defense World
Tocqueville Asset Management L.P. Makes New Investment in TScan Therapeutics, Inc. (NASDAQ:TCRX) - MarketBeat
TScan Therapeutics, Inc. (NASDAQ:TCRX) Short Interest Update - American Banking and Market News
Short Interest in TScan Therapeutics, Inc. (NASDAQ:TCRX) Grows By 18.7% - Defense World
Head to Head Comparison: TScan Therapeutics (NASDAQ:TCRX) and Monte Rosa Therapeutics (NASDAQ:GLUE) - Defense World
TScan Therapeutics, Inc. (NASDAQ:TCRX) Sees Large Increase in Short Interest - MarketBeat
A new trading data show Tscan Therapeutics Inc (TCRX) is showing positive returns. – Sete News - SETE News
Should investors be concerned about Tscan Therapeutics Inc (TCRX)? – US Post News - US Post News
In the Green: Tscan Therapeutics Inc (TCRX) Closes at 5.85, Up/Down -6.25 from Previous Day – DWinneX - The Dwinnex
TScan’s TCR-Ts Get RMAT Designation for Hematologic Malignancies - CGTLive™
Favourable Signals For TScan Therapeutics: Numerous Insiders Acquired Stock \ - Yahoo News Australia
TCRX overperforms with a 2.13 increase in share price – US Post News - US Post News
It is Poised to be a Bull Market for Tscan Therapeutics Inc (TCRX) – Sete News - SETE News
The Significance of Moving Averages in Tscan Therapeutics Inc Inc. (TCRX) Price Performance - The InvestChronicle
Strength Seen in Zealand Pharma AS (ZLDPF): Can Its 11.6% Jump Turn into More Strength? - Zacks Investment Research
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Capitalizzazione:
|
Volume (24 ore):